Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
IRELAND IS TO receive 300,000 fewer vaccine doses up to the end of March than was previously expected due to the supply issues related to the Oxford/AstraZeneca jab.
Chair of the vaccination task force Brian MacCraith told and Oireachtas Committee today that that Ireland is expected to have 1.1 million doses by the end of March, down from the previously expected 1.4 million.
This is due to the “significant drop” in the expected deliveries from AstraZeneca.
MacCraith said it is expected that 191,000 doses of the AstraZeneca vaccine will be delivered in February, with just 95,000 currently confirmed for March.
Advertisement
The reduction means that 550,000 people can be vaccinated in that period – about 150,000 fewer than the government’s 700,000 target.
MacCraith added that there is no certainty over the supply of vaccines from April onwards and the the task force was “sticking to the principle of administering vaccines as soon as they arrive”.
“We have a level of confidence for this quarter but that has been dented in the weeks and days due to AstraZeneca situation,” MacCraith said.
The assurances we had received indicated 1.4 million doses across AstraZeneca, Pfizer and Moderna and naturally the simple calculation, given they’re all dual doses, leads to 700,000 people being vaccinated.
“However, as we learned in recent days, AstraZeneca has indicated a significant drop. So currently that 1.4 million doses has dropped to just above 1.1 million doses.”
TDs also asked a number of questions about the potential role of pharmacists in the vaccine delivery programme, with the HSE’s David Walsh saying they may be part of the vaccination of over 70s.
Over 70s are the next cohort in line to be vaccinated after the completion of the first two priority groups; healthcare workers and those in care homes.
TDs and senators were told that an average of 48,000 doses of vaccine have been administered per week over the past three weeks. Representatives from the HSE also said that it would be “a week or two” before daily vaccination figures could be provided.
Related Reads
EU medicines agency approves Oxford/AstraZeneca Covid-19 vaccine for everyone over 18
Amid a deepening row, the [heavily redacted] EU-AstraZeneca contract has been published
German authorities said yesterday that there is insufficient evidence for its efficacy for people aged over 65.
“Obviously an awful lot depends on what we hear today as regards the AstraZeneca vaccine and whatever determination that the European Medicines Agency come to in that regard, and whether they make any comment on the age dimension, a bit like what we heard in Germany,” MacCraith said.
“The plan originally was certainly that the AstraZeneca vaccine would be used through the GP network to address cohort number three, which is the over 70s, if for any reason that doesn’t happen, the contingency plan at this stage is to use the Pfizer/BionTech and the Moderna vaccines for that cohort.”
Asked whether this could be done through the GP system, MacCraith said that it “is a possibility” because the Pfizer/BionTech vaccine was used by GPs in the UK.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
TheJournal.ie's Coronavirus Newsletter
TheJournal.ie's coronavirus newsletter cuts through the misinformation and noise with the clear facts you need to make informed choices. Sign up here
To embed this post, copy the code below on your site
Close
39 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
So many questions about AstraZeneca now. Many older people who were expecting to receive this vaccine are now worried that it will not be effective for them. We have been told that we cannot pick or choose the vaccine we receive. The government and our minister for health needs to address the questions around the efficiency of this vaccine for our oldest and most vulnerable citizens. This vaccine was supposed to be the answer for poorer nations who will struggle to afford other vaccines produced by big Pharma, but now AstraZenecas integrity has been thrown into question. We need answers.
@Teresa O’Halloran: also I know people in the uk, both young and old who felt very ill the day after receiving the jab. Don’t know about any of the other vaccines?
@Ian James Burgess: Who are these people you talk about? I know you know is not a fact. They aren’t complaining in the UK they are being vaccinated in their millions while we wait in line for Merkel & Von De Liar to get over themselves & now Novavax is about to be approved by the UK again they have their own manufacturing site on Teeside. When news talk asked our minister about supplies he said we were behind the commission & when he pushed further that the UK may offer to help Ireland with supplies if they were to help anyone because of the land border he said Ireland would refuse this help & show solidarity with the EU instead???
@Ian James Burgess: I know several people in the U.K. who have had both AZ and Pfizer vaccines. They’ve had no or minor side effects that are usual for any vaccine. I also have family members who are both involved in the roll out of the vaccine programme so would see any serious side effects being reported and who were involved as part of the Oxford University team. The vaccine is completely safe for over 65s and evidence is that they will have a comparable level of protection since blood tests show they have similar numbers of antibodies to younger people. There is no evidence at all to suggest that the vaccine won’t work for over 65s and in fact, the German politician who created this doubt has just rolled back on his comments.
@Paul Keenan: I was just looking for any side effects of any of the vaccines, not arguing about not getting it. Just be nice to have peoples different reactions.
@Ian James Burgess: I felt awful the day after getting the third dose of the hep B vaccine. It’s normal for vaccines to make some people feel sick for a couple of days.
@John McCann: we are not at the back of the queue. The contract has previously been signed. The uk rushed in and approved it to be the brexit poster boys. The EU are going through the proper channels of approval.
@Brian Madden: Britain went through their proper channels as well but they were more effective as instead of waiting for the final results to be published they had a method of working together with the companies so they were analysing the data as it was becoming available.
Nothing to do with Brexit everything to do with the country being in a dire situation and desperate to get out of it.
@David Fülöp: the EU have been using the rolling review process too. The UK approved it on data that was not acceptable to either the EMA in Europe or the FDA in the USA. AstraZeneca had to complete extra trials before the EMA or FDA would consider approval. Says something about the UK’s system.
@Brian Madden: I’d have said Boris’s cabinet rather than UK. We’ve kinda forgotten that he’s a looney surrounding himself with equally crazy loyalists. Events have elevated/normalised them.
@Ger Murray: There’s weight to this. I can’t imagine how gutting it is for AstraZeneca to be selling this at cost when its clearly a home run product in gigantic demand.
@JillyBean: They’ve a get out clause. They are only selling the drug at cost as long as there is a pandemic and they get to say when the pandemic ends, at the moment it’s set to end July 1st 2021:
@Steve: Could short supplying the EU intially to bulk supply after the 1st July be a means of charging more? OR does this contract set out a price per dose for the 400 Million ordered?
@JillyBean: I believe it was the Oxford University that developed the vaccine, paid for by the taxpayer. The drug company is about trials and production and profit. Part of the deal was that they would make it available at cost during the pandemic, and rightly so. Personally I believe no life saving drug should be withheld from any country due to poverty; to do nothing when it is within your ability to save a person is not really different to manslaughter.
Meanwhile the EU have thrown more petrol on the flames this morning with ill thought out radio interviews. The EU placed our order after other countries so of course we are behind in the queue. Trying to argue that when you placed your order doesn’t matter is ridiculous. If another 30 or 40 countries place an order later today are the EU really going to say that the available vaccines should be shared out equally with all of them too. This is showing the worst of the EU – they create a bureaucratic mess and then look around to see who they can blame. They started with Astra Zeneca (the only company producing the vaccine for no profit) saying they were favouring those who paid more and now there’s a comment suggesting that the U.K. wants a vaccine war but U.K. has said no such thing.
@Sara Davis: the mad thing is that; until vaccines are rolled out across the entire globe we will not be in any way resilient against this virus, so, personally I don’t mind which country gets it first, as long as the rollout is completed in a timely manner.
The EU ought to hang their heads in shame. They’ve made a complete mess of this vaccine roll out. Countries having to pause or cease their programs finger pointing and whinging about other non EU countries. Shambolic.
We need to get Bono or Bob Geldof to address the European parliament, and tell them the urgency of getting the vaccine out to all citizens of Europe and beyond. After all it’s a matter of life.
Conor McGregor's appeal against jury finding in civil sexual assault case to be heard next week
3 hrs ago
5.3k
Tariffs
Trump pledges to double tariffs on Canada's steel and aluminium to 50%
Updated
1 hr ago
23.4k
88
Courts
Woman who was raped by three men she met at Dublin nightclub says she was treated as 'an object'
23 hrs ago
49.9k
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 156 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 106 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 137 partners can use this purpose
Use limited data to select advertising 106 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 79 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 78 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 38 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 34 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 127 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 60 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 75 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 82 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 39 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 45 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 27 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 89 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 96 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 71 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 52 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 86 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 66 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say